NCT02619526

Brief Summary

Heart failure (HF) is a common and disabling condition in the elderly. Randomized clinical trials and meta-analyses have clearly demonstrated that long-term use of β blockers improves the outcomes of patients with HF. However, limited data have been available on the treatment of HF with preserved ejection fraction (EF) in the elderly. No study has specifically compared the relative effectiveness of carvedilol and nebivolol in treating HF in old age patients with preserved EF.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
62

participants targeted

Target at P25-P50 for not_applicable heart-failure

Timeline
Completed

Started Dec 2016

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 25, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 2, 2015

Completed
1 year until next milestone

Study Start

First participant enrolled

December 1, 2016

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2018

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

February 5, 2018

Status Verified

February 1, 2018

Enrollment Period

1.6 years

First QC Date

November 25, 2015

Last Update Submit

February 2, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • the ratio of transmitral E velocity to early diastolic mitral annular velocity (E/E')

    12 months

Study Arms (2)

Nebivolol

EXPERIMENTAL

Nebivolol 10mg, once a day

Drug: Nebivolol

Carvedilol

ACTIVE COMPARATOR

Carvedilol 25mg, twice a day

Drug: Carvedilol

Interventions

Nebivolol 10mg, once a day

Nebivolol

Carvedilol 25mg, twice a day

Carvedilol

Eligibility Criteria

Age70 Years - 95 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • more than 70 years
  • EF ≥ 40%

You may not qualify if:

  • contraindication to the study drug

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Internal Medicine,Dong-A University College of Medicine

Busan, South Korea

RECRUITING

Related Publications (1)

  • Park K, Park TH. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. Trials. 2016 Nov 3;17(1):530. doi: 10.1186/s13063-016-1656-y.

MeSH Terms

Conditions

Heart Failure

Interventions

NebivololCarvedilol

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesBenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingPropanolaminesPropanolsCarbazolesIndolesHeterocyclic Compounds, 3-Ring

Study Officials

  • Tae-Ho Park, MD

    Dong-A University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

November 25, 2015

First Posted

December 2, 2015

Study Start

December 1, 2016

Primary Completion

July 1, 2018

Study Completion

December 1, 2018

Last Updated

February 5, 2018

Record last verified: 2018-02

Locations